魏芳 - 上海交通大学 - 生命科学技术学院

个人简介

先后从事肿瘤组织比较基因组学、博莱霉素衍生物抗肿瘤敏感性、基因改变与B/T细胞淋巴瘤形成，以及肿瘤免疫逃逸与治疗等研究方向。留美期间所在实验室在个体化免疫治疗研究与临床实践处于世界领先水平。2013年全职回国后，继续从事CAR和PD-1介导不同类型肿瘤的T细胞过继治疗和ALK蛋白诱癌分子机理研究。已发表第一及共同作者SCI文章20篇，其中包括在PNAS、American J Pathology、Science Translation Medicine、EMBO J、Mol Cell Biol、J Biol Chem、和Cancer Research等杂志；研究结果申请美国专利1项。 2013 – 副研究员上海交通大学生命科学技术学院盛毓绶细胞与免疫学研究中心 2010 - 2013 研究助理宾夕法尼亚大学医学院Abramson肿瘤研究所 2008 - 2010 博士后宾夕法尼亚大学医学院Abramson肿瘤研究所 2005 - 2008 博士后宾夕法尼亚大学兽医医学院比较肿瘤研究所及动物生物学系 2003 - 2005 研究助理弗吉尼亚大学化学系 2000 - 2003 博士中国协和医科大学肿瘤研究所分子肿瘤学国家重点实验室 1997 - 2000 硕士华中农业大学生命科学院农业微生物国家重点实验室 1994 - 1997 学士华中农业大学生命科学院

研究领域

肿瘤的发生发展及免疫治疗，慢性病毒及肿瘤的免疫逃逸

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Zhang L*, Zhu C*, Guo Y*, Wei F*, Lu J, Qin J, Banerjee S, Wang J, Shang H, Verma SC, Yuan Z, Robertson ES, Cai Q. Inhibition of KAP1 enhances hypoxia-induced KSHV reactivation through RBP-Jk. J Virol, 88(12):6873-84, 2014 (*co-first author) Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman G, Krogsgaard M, and Riley JR*. Strength of PD-1 Signaling Differentially Affects T Cell Effector Functions. PNAS, 110: e2480-2489, 2013 Zhang Q*, Wei F*, Wang H, Liu X, Roy D, Xiong Q, Jiang S, Medvec A, Danet-Desnoyers G, Watt C, Tomczak E, Kalos M, Riley JL*, Wasik M*. A single oncogene NPM-ALK mediates malignant transformation of normal human CD4+ T lymphocytes. Am J Pathol，183(6):1971-80, 2013 (*co-first author) Zhang Q, Wang HY, Wei F, Liu XB, Paterson JC, Roy D, Mihova D, Woetmann A, Ptasznik A, Odum N, Schuster SJ, Marafioti T, Riley J, and Wasik MA*. Cutaneous T-cell lymphoma (CTCL) expresses immunesuppressive CD80 (B7-1) cell-surface protein in the STAT5-dependent manner. J Immunol, 192:000-000, 2014 Pan X, Papasani M, Hao Y, Calamito M, Wei F, Quinn III W, Wang JW, Hodawadekar S, Zaprazna K, Liu HF, Shi Y, Allman D, Cancro M, and Atchison ML*. The YY1 REPO Domain Controls Igk Repertoire, B Cell Development and Co-localizes with Condensin Complex Proteins on the Igκ Locus, EMBO J, 32(8):1168-82, 2013 Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, Levine BL, June CH, Medin JA, Fowler DH*. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med, 3(111):111-120, 2011 Wei F, Zaprazna K, Wang J, Atchison ML*. PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells. Mol Cell Biol, 29(17):4612-22, 2009. Wei F, Scholer HR, Atchison ML*. Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation transactivation. J Biol Chem,282(29): 21551-60, 2007. Ma Q, Xu ZD, Schroeder BR, Sun WY, Wei F, Hashimoto S, Konishi K, Leitheise CJ, Hecht SM*. Biochemical evaluation of a 108-member deglycobleomycin library: viability of a selection strategy for identifying bleomycin analogues with altered properties. J Am Chem Soc, 129, 12439-52, 2007. Hodawadekar S, Wei F, Yu D, Thomas-Tikhonenko A, Atchison ML*. Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. J Immunol, 177(9):6165-71, 2006. Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, Zhang X, Sun YT, Zhan QM, Wu M, Wang MR*. Amplification and overexpression of CTTN (EMS1)contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 66(24):11690-9, 2006. Wei F, Ni J, Wu SS, Liu H, Xu X, Han YL, Cai Y, Zhang JW, Chen XJ, Pang H, Lu N, Ji, Wu M, Wang MR*. Cytogenetic studies of esophageal squamous cell carcinomas in the northern Chinese population by comparative genomic hybridization. Cancer Genet Cytogenet, 138(1): 38-43, 2002.